Cross-platform analytical assessment of serum GFAP quantification in multiple sclerosis: SIMOA versus two automated immunoassays.

ABSTRACT:

Introduction

Serum glial fibrillary acidic protein (sGFAP) is a promising biomarker, but its quantification mainly relies on SIMOA, a technology not widely available in clinical practice.

Objectives

To evaluate the analytical performance of two high-throughput automated platforms-Alinity^® i (Abbott) and Lumipulse^® G1200 (Fujirebio)-for sGFAP quantification.

Methods

A retrospective longitudinal study included 107 serum samples from 23 MS patients. sGFAP was measured with SIMOA SR-X^®, Lumipulse^® G1200, and Alinity^® i. Data were log-transformed. Agreement was assessed using Pearson correlations, Passing-Bablok regression, Bland-Altman analysis, and Δlog correlations between visits. Longitudinal differences across pla

SUBMITTER: Tortosa-Carreres J 

PROVIDER: S-EPMC12580120 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature